The stock of Aerie Pharmaceuticals Incorporated (NASDAQ:AERI) registered a decrease of 0.57% in short interest. AERI’s total short interest was 4.68 million shares in September as published by FINRA. Its down 0.57% from 4.71M shares, reported previously. With 338,000 shares average volume, it will take short sellers 14 days to cover their AERI’s short positions. The short interest to Aerie Pharmaceuticals Incorporated’s float is 34.08%. About 360,839 shares traded hands. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 51.82% since February 8, 2016 and is uptrending. It has outperformed by 35.33% the S&P500.
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The company has a market cap of $563.26 million. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It currently has negative earnings. The Company’s primary product candidates are Rhopressa and Roclatan.
The institutional sentiment increased to 1.67 in 2016 Q2. Its up 0.28, from 1.39 in 2016Q1. The ratio is positive, as 11 funds sold all Aerie Pharmaceuticals Inc shares owned while 22 reduced positions. 9 funds bought stakes while 46 increased positions. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1.
Foresite Capital Management Ii Llc holds 11.73% of its portfolio in Aerie Pharmaceuticals Inc for 975,285 shares. Dafna Capital Management Llc owns 160,869 shares or 2.24% of their US portfolio. Moreover, Deerfield Management Co has 1.74% invested in the company for 2.52 million shares. The California-based Partner Investment Management L.P. has invested 1.28% in the stock. Partner Fund Management L.P., a California-based fund reported 2.34 million shares.
Out of 7 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $50 is the highest target while $40 is the lowest. The $45.71 average target is 135.25% above today’s ($19.43) stock price. Aerie Pharmaceuticals has been the topic of 9 analyst reports since September 17, 2015 according to StockzIntelligence Inc. Cantor Fitzgerald reinitiated the stock on June 3 with “Buy” rating. Stifel Nicolaus maintained the shares of AERI in a report on September 17 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.